2023 - Research.com Medicine in Italy Leader Award
2023 - Research.com Immunology in Italy Leader Award
2022 - Research.com Immunology in Italy Leader Award
2018 - Member of Academia Europaea
His main research concerns Allergy, Immunology, Asthma, Intensive care medicine and Internal medicine. Particularly relevant to Allergen immunotherapy is his body of work in Allergy. His studies in Asthma integrate themes in fields like Surgery, MEDLINE, Quality of life, Family medicine and Disease.
His Intensive care medicine study integrates concerns from other disciplines, such as Sublingual immunotherapy, Postmarketing surveillance, Adverse effect, Quality of life and Alternative medicine. His work on Clinical trial and Clinical endpoint as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. As a part of the same scientific study, Giorgio Walter Canonica usually deals with the Randomized controlled trial, concentrating on Pharmacotherapy and frequently concerns with Physical therapy.
Immunology, Asthma, Allergy, Internal medicine and Intensive care medicine are his primary areas of study. Allergen, Immunotherapy, Immunoglobulin E, Inflammation and Allergic inflammation are the primary areas of interest in his Immunology study. His Asthma study incorporates themes from Clinical trial, MEDLINE, Adverse effect, Family medicine and Disease.
His work on Allergen immunotherapy as part of general Allergy research is often related to Slit, thus linking different fields of science. His work deals with themes such as Gastroenterology, Placebo and Endocrinology, which intersect with Internal medicine. His Intensive care medicine research is multidisciplinary, incorporating elements of Alternative medicine, COPD and Quality of life.
Giorgio Walter Canonica mainly investigates Asthma, Internal medicine, Intensive care medicine, Allergy and Severe asthma. His research in Asthma intersects with topics in Family medicine, Gastroenterology and MEDLINE. Giorgio Walter Canonica has researched Intensive care medicine in several fields, including Allergen immunotherapy, mHealth, Disease and Quality of life.
His research integrates issues of Allergists, Pharmacotherapy, Pandemic and Atopic dermatitis in his study of Allergen immunotherapy. His Allergy research entails a greater understanding of Immunology. The study incorporates disciplines such as Corticosteroid, Clinical trial and Medical history in addition to Adverse effect.
His scientific interests lie mostly in Asthma, Internal medicine, Intensive care medicine, Adverse effect and Allergy. His studies deal with areas such as Integrated care, Family medicine, COPD, Severity of illness and Cohort as well as Asthma. His Family medicine research is multidisciplinary, incorporating perspectives in Psychological intervention and MEDLINE.
He has included themes like mHealth, Disease, Review article, Atopic dermatitis and Chronic rhinosinusitis in his Intensive care medicine study. The Adverse effect study combines topics in areas such as Clinical endpoint, Clinical trial, Sarilumab, Placebo and Corticosteroid. His Allergy study is focused on Immunology in general.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs
J. Bousquet;H. J. Schünemann;B. Samolinski;P. Demoly.
The Journal of Allergy and Clinical Immunology (2012)
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
J. Bousquet;N. Khaltaev;A. A. Cruz;J. Denburg.
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
Jan L. Brożek;Jean Bousquet;Ioana Agache;Arnav Agarwal.
The Journal of Allergy and Clinical Immunology (2017)
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
M. Humbert;R. Beasley;J. Ayres;R. Slavin.
Consensus statement * on the treatment of allergic rhinitis
P van Cauwenberge;C Bachert;G Passalacqua;J Bousquet.
Practical guide to skin prick tests in allergy to aeroallergens
J. Bousquet;J. Bousquet;L. Heinzerling;C. Bachert;N. G. Papadopoulos.
Standards for practical allergen-specific immunotherapy
E. Alvarez-Cuesta;J. Bousquet;G. W. Canonica;S. R. Durham.
Sub-lingual immunotherapy: World Allergy Organization Position Paper 2009.
Canonica Gw;Bousquet J;Casale T;Lockey Rf.
Allergen immunotherapy: therapeutic vaccines for allergic diseases
J. Bousquet;R. Lockey;H.J. Malling;E. Alvarez-Cuesta.
Annals of Allergy Asthma & Immunology (1998)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert;Claus Bachert;Joseph K Han;Martin Desrosiers;Peter W Hellings.
The Lancet (2019)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: